Eyegate Pharmaceuticals Inc fka EYEG

[crudeoil24]

Eyegate Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company that is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. EGP-437 is the first and only product in clinical trials, and incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, that is delivered into the ocular tissues though the Company’s proprietary drug delivery system, the EyeGate II Delivery System. EGP-437 is being developed under the 505(b)(2) New Drug Application (NDA), regulatory pathway for drugs submitted for approval to the United States Food and Drug Administration (FDA). The Company is also exploring the potential use of the EyeGate II Delivery System to provide a non-invasive solution for treating other, more prevalent retinal diseases, like age-related macular degeneration, the two primary drug treatments.

http://www.eyegatepharma.com